Bruyère Research Institute, 43 Bruyère St., K1N 5C8, Ottawa, Ontario, Canada; Concordia University, Montreal, Quebec, Canada.
Bruyère Research Institute, 43 Bruyère St., K1N 5C8, Ottawa, Ontario, Canada; Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada; School of Pharmacy, University of Waterloo, Waterloo, Canada.
Res Social Adm Pharm. 2019 Jun;15(6):796-800. doi: 10.1016/j.sapharm.2018.08.012. Epub 2018 Sep 18.
A Bruyère Evidence-Based Deprescribing Guideline Symposium was held in March 2018; one component focused on implementing deprescribing guidelines into practice. An interactive discussion activity allowed the 107 participants to share experiences and ideas concerning the barriers and facilitators that arise when moving deprescribing guidelines into frontline practice. Participants identified 8 broad challenges and problem areas. These included challenges and barriers that arise in the daily practices of pharmacists and prescribers and in other health care settings, and those related to existing policies, processes, and financial structures. They also identified 10 factors that facilitated implementation efforts, including: educating patients, caregivers, health care providers (HCPs) and staff; improving collaboration across practice disciplines; expanding the evidence for deprescribing; and fostering organizational cultures of deprescribing. The results indicate that participants are committed to deprescribing and are moving forward with efforts to bring about change. Participants recognize that the implementation of deprescribing is best conceived of as a comprehensive systems change, and that patients and the public need to be involved in deprescribing processes and activities.
2018 年 3 月举行了布鲁耶尔循证药物减量指南研讨会;其中一个部分的重点是将药物减量指南付诸实践。一项互动讨论活动使 107 名参与者能够分享在将药物减量指南付诸一线实践时出现的障碍和促进因素方面的经验和想法。参与者确定了 8 个广泛的挑战和问题领域。这些挑战和障碍不仅存在于药剂师和处方者的日常实践中,也存在于其他医疗保健环境中,还涉及到现行政策、流程和财务结构。他们还确定了 10 个促进实施工作的因素,包括:对患者、护理人员、医疗保健提供者(HCP)和工作人员进行教育;改善跨实践学科的协作;扩大药物减量的证据基础;培养药物减量的组织文化。结果表明,参与者致力于药物减量,并正在努力推动变革。参与者认识到,实施药物减量最好被视为一个全面的系统变革,并且患者和公众需要参与药物减量的过程和活动。